Risankizumab-Rzaa
3 NDCs across 1 manufacturer|0 Generic,3 Brand
Risankizumab-Rzaa is used to treat psoriasis, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
In 2024, Medicare Part D spent $2.5 billion on Risankizumab-Rzaa across 122,000 claims for 37,000 beneficiaries.
Risankizumab-Rzaa is available as 3 NDCs from 1 manufacturer (0 generic, 3 brand), with NADAC prices from $9572.67 to $22887.44 per ML — the most expensive product costs about 2.4× the cheapest. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
3
0G / 3B
Manufacturers
1
competing in market
Price Spread
$9572.67 – $22887.44
per ML
7d Activity
avg +0.1% WoW · of 3 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Explore this market from other angles
Move from the molecule page into the supplier, class, and trend views that create the strongest internal-link cluster for this market.
Top supplier
AbbVie Inc. manufacturer profile
Open the supplier page for the manufacturer with the strongest footprint in this market.
Lead class
Interleukin-23 Antagonist class view
See how this market rolls up into the broader therapeutic class and compare other drugs in the same bucket.
Trend hub
Latest market trends
Move from this single molecule into the current cross-market mover and volatility view.
Guide
How to interpret NADAC
Review the benchmark methodology behind the prices and spreads shown on this market page.
Manufacturer Breakdown
1 manufacturer producing RISANKIZUMAB-RZAA
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
SKYRIZI 150 MG/ML SYRINGE | $22887.4386 per ML | — |
SKYRIZI 150 MG/ML PEN | $22774.3609 per ML | +0.06% |
SKYRIZI 360 MG/2.4 ML ON-BODY | $9572.6650 per ML | +0.07% |
Frequently Asked Questions
What is Risankizumab-Rzaa used to treat?
Risankizumab-Rzaa is used to treat psoriasis, per the National Library of Medicine's MED-RT classification.
How much does Medicare spend on Risankizumab-Rzaa?
In 2024, Medicare Part D spent $2.5 billion on Risankizumab-Rzaa across 122,000 claims for 37,000 beneficiaries.
How many Risankizumab-Rzaa products are on the market?
The Risankizumab-Rzaa drug market contains 3 NDCs from 1 manufacturer — 0 generic and 3 brand products.
What is the price range for Risankizumab-Rzaa?
NADAC reference prices for Risankizumab-Rzaa range from $9572.6650 to $22887.4386 per ML — the most expensive product costs about 2.4× the cheapest.
Which manufacturers make Risankizumab-Rzaa?
1 manufacturer lists Risankizumab-Rzaa in NADAC. Ranked by number of NDCs, the largest are AbbVie Inc. (3).
How has the price of Risankizumab-Rzaa changed recently?
Over the past 7 days, 2 Risankizumab-Rzaa NDCs rose and 0 fell, with a market-wide average change of +0.1%.